Postgraduate Biotechnology 2016-2017

This course will describe the basic language of business and give examples of large versus small businesses in the bioscience area.  Intellectual property rights will be explained as will how present your business and how to set up a small biotech company.    A comparison will be made of the big Pharma business model and that of small biotech businesses.

The course will focus on small molecule drug discovery.  Receptor theory and cell communication and signalling will be revised to facilitate understanding of the remainder of the course. The basis of the drug discovery process will be described and the phases of drug development discussed.  A range of targets for drug discovery will be identified and how small molecule drug affect these will be described.  Issues around drug regulation will be raised.

This is a short introductory course to outline the basics of the commercialisation of bio scientific ideas.

The main aim of this course is to introduce you to the language of business and demystify some of the jargon that surrounds business models, intellectual property rights (IPR) and finance. This is an opportunity to understand the basics of Bio-business and the commercialisation of bioscience.

This advanced course builds on the basics provided in Introduction to Bio-business and the Commercialisation of Bioscience Research (BT5012).  It provides more detail on financing and setting up a Bio-business.

The course deals in depth with finance, corporate governance and business models. The major assessment involves the students working together in teams to set up a virtual bio-business and to pitch this business to a group of experts in the pharmaceutical and biotechnology sector. The team will adopt the roles of senior management team and present to the experts their part of the business.

This course is aimed at the understanding of novel areas of drug discovery with the specific aim of understanding the roles immunology and peptide chemistry play in informing the development of antibody and small molecule peptide-based biologic therapies for diverse diseases.